An accompanying comment notes that the importance of this study relates to the unique mechanism of action of trebananib, which unlike other anti-angiogenic drugs tested in the phase 3 ovarian cancer setting, targets the binding of angiopoietins 1 and 2 to the Tie 2 receptor rather than the VEGF pathway. The author suggests that evidence of significant benefit—although a modest 1.8 months—is especially welcome in this setting. The finding also raises the possibility of studies of combinations of anti-angiogenic drugs given either concomitantly, sequentially, or alternately to increase duration of effect.